A comprehensive procedural approach to genotyping KRAS and BRAF from paraffin embedded tissues for diagnostic purposes

In Vivo

Volumn 26, Issue 4, 2012, Pages 537-548

  Palmirotta, Raffaele ^a   Ludovici, Giorgia ^a   De Marchis, Maria Laura ^a   Leone, Barbara ^a   Formica, Vincenzo ^b   Ettorre, Giuseppe Maria ^c   Cavaliere, Francesco ^d   Della Morte, David ^a,e   Ferroni, Patrizia ^a   Roselli, Mario ^b   Guadagni, Fiorella ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d MOLINETTE HOSPITAL   (Italy)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF; Colorectal cancer; Concurrent mutation; Genotyping; KRAS; Mutational analysis

Indexed keywords

B RAF KINASE; PARAFFIN;

ADULT; AGED; ALLELE; ARTICLE; CANCER GENETICS; CANCER PATIENT; CANCER TISSUE; CLONING; CODON; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DNA EXTRACTION; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICRODISSECTION; MUTATION RATE; ONCOGENE K RAS;

EID: 84865102534     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Savonarola A, Palmirotta R, Guadagni F and Silvestris F: Pharmacogenetics and pharmacogenomics: role of mutational analysis in anticancer targeted therapy. Pharmacogenomics J (in press).
2. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F and Salomon DS: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16, 2006. (Pubitemid 43199589)
3. Jancík S, Drábek J, Radzioch D and Hajdúch M: Clinical relevance of KRAS in human cancers. J Biomed Biotechnol Volume 2010, Article ID 150960, 2010.
4. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E and Ciardiello F: Implications for KRAS status and EGFRtargeted therapies in metastatic CRC. Nat Rev Clin Oncol 6: 519-527, 2009.
5. Tímár J, Hegedüs B and Rásó E: KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence. Curr Cancer Drug Targets 10: 813-823, 2010.
6. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL: Genetic alterations during colorectal tumor development. N Engl J Med 319: 525-532, 1988.
7. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61 : 759-767, 1990.
8. Malumbres M and Barbacid M: RAS oncogenes: The first 30 years. Nat Rev Cancer 3: 459-465, 2003. (Pubitemid 37328850)
9. Martinez-Garza SG, Núñez-Salazar A, Calderon- Garcidueñas AL, Bosques-Padilla FJ, Niderhauser-García A and Barrera- Saldaña HA: Frequency and clinicopathology associations of KRAS mutations in colorectal cancer in a Northeast Mexican population. Digest Dis 17: 225-229, 1999.
10. Uroseviæ N, Krtolica K, Skaro-Miliæ A, Knezeviæ-Usaj S and Dujiæ A: Prevalence of G-to-T transversions among KRAS oncogene mutations in human colorectal tumors in Yugoslavia. Int J Cancer 54: 249-254, 1993.
11. Palmirotta R, Savonarola A, Formica V, Ludovici G, Del Monte G, Roselli M and Guadagni F: A novel KRAS mutation in colorectal cancer. A case report and literature review. Anticancer Res 29: 3369-3374, 2009.
12. Palmirotta R, Savonarola A, Ludovici G, De Marchis ML, Covello R, Ettorre GM, Ialongo C and Guadagni F: Concurrent mutation in exons 1 and 2 of KRAS oncogene in colorectal cancer. Folia Histochemica Cytobiologica 49: 729-733, 2011.
13. Edkins S, O'Meara S, Parker A, Stevens C, Reis M, Jones S, Greenman C, Davies H, Dalgliesh G, Forbes S, Hunter C, Smith R, Stephens P, Goldstraw P, Nicholson A, Chan TL, Velculescu VE, Yuen ST, Leung SY, Stratton MR and Futreal PA: Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 5 : 928-932, 2006.
14. Goldstein NS and Armin M: Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92: 1331- 1346, 2001.
15. Andreyev HJ, Norman AR, Cunningham D, Oates JR and Clarke PA: Kirsten RAS mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. J. Natl Cancer Inst 90: 675- 684, 1998
16. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lövig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K and Urosevic N: Kirsten RAS mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 85: 692-696, 2001.
17. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD and Chang DD: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 : 1626-1634, 2008.
18. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, B?asi?ska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M and Gansert J: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705, 2010.
19. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M and Koralewski P: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22: 1535-1546, 2011.
20. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P and Ciardiello F: Cetuximab plus irinotecan, fluorouracil, and leucovorin as firstline treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011-2019, 2011.
21. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S and Bardelli A: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26 : 5705-5712, 2008.
22. Lamy A, Blanchard F, Le Pessot F, Sesboüé R, Di Fiore F, Bossut J, Fiant E, Frébourg T and Sabourin JC: Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Mod Pathol 24: 1090-1100, 2011.
23. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S and Bardelli A: PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFRtargeted monoclonal antibodies. Cancer Res 69: 1851-1857, 2009.
24. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S and Falcone A: PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27: 2622-2629, 2009.
25. Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, Fieuws S, Vandesompele J, Peeters M, Van Laethem JL, Humblet Y, Pénault-Llorca F, De Hertogh G, Laurent-Puig P, Van Cutsem E and Tejpar S: Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 27: 5068-5074, 2009.
26. van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, Quirke P, Fléjou JF, Plato Hansen T, de Hertogh G, Jares P, Langner C, Hoefler G, Ligtenberg M, Tiniakos D, Tejpar S, Bevilacqua G and Ensari A: KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 453: 417-423, 2008.
27. Russo A, Bazan V, Agnese V, Rodolico V and GebbiaN: Prognostic and predictive factors incolorectal cancer: Kirsten RAS in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol 4 : 44-49, 2005.
28. Perspectives on Emerging Technology (POET). Report: KRAS Mutation Testing for Colorectal Cancer (CRCs). College of American Pathologists: Northfield, IL, USA 2009.
29. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F and Laurent-Puig P: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379, 2008.
30. Neumann J, Zeindl-Eberhart E and Kirchner T: Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathology Res Pract 205: 858-862, 2009.
31. Vaughn CP, Zobell SD, Furtado LV, Baker CL and Samowitz WS: Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 50 : 307-312, 2011.
32. Smith G, Bounds R, Wolf H, Steele RJ, Carey FA and Wolf CR: Activating KRAS mutations outwith 'hot-spot' codons in sporadic colorectal tumours - implications for personalised cancer medicine. Br J Cancer 102: 693-703, 2010.
33. Wilentz RE, Goggins M, Redston M, Marcus VA, Adsay NV, Sohn TA, Kadkol SS, Yeo CJ, Choti M, Zahurak M, Johnson K, Tascilar M, Offerhaus GJ, Hruban RH and Kern SE: Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. Am J Pathol 156 : 1641-1651, 2000. (Pubitemid 30646702)
34. Naguib A, Mitrou PN, Gay LJ, Cooke JC, Luben RN, Ball RY, McTaggart A, Arends MJ and Rodwell SA: Dietary, lifestyle and clinicopathological factors associated with BRAF and KRAS mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. BMC Cancer 10 : 99, 2010.
35. Miyakura Y, Sugano K, Fukayama N, Konishi F and Nagai H: Concurrent mutations of KRAS oncogene at codons 12 and 22 in colon cancer. Jpn J Clin Oncol 32: 219-221, 2002. (Pubitemid 41289001)
36. Kimura K, Nagasaka T, Hoshizima N, Sasamoto H, Notohara K, Takeda M, Kominami K, Iishii T, Tanaka N and Matsubara N: No duplicate KRAS mutation is identified on the same allele in gastric or colorectal cancer cells with multiple KRAS mutations. J Int Med Res 35: 450-457, 2007. (Pubitemid 47261106)
37. Guo Z, Lu Y, Oakes S, Britton A, King T, Huang K, Tzenova V, Ferraro J, Apelian D and Franzusoff A: Transnational patterns of pancreas cancer RAS mutations and discovery of a new RAS mutation with oncogenic synergy when found with RAS codon 12 mutations. 20th EORTC-NCI-AACR symposium on "Molecular targets and Cancer Therapeutics" Geneva, Switzerland, 21-24 October 2008, Poster presentation # 22.
38. Losi L, Baisse B, Bouzourene and Benhattar J: Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 26: 916-922, 2005. (Pubitemid 41214320)
39. Sweeney C, Boucher KM, Samowitz WS, Wolff RK, Albertsen H, Curtin K, Caan BJ and Slattery ML: Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors. Genes, Chromosomes Cancer 48 : 1-9, 2009.
40. PS, Erlich HA and Higuchi R: Preferential PCR amplification of alleles: mechanisms and solutions. Walsh PCR Meth 1: 241-250, 1992.
41. Do H and Dobrovic A: Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies. Mol Cancer 8: 82, 2009.
42. Rouleau E, Spyratos F, Dieumegard B, Guinebretière JM, Lidereau R and Bièche I: KRAS mutation status in colorectal cancer to predict response to EGFR-targeted therapies: the need for a more precise definition. Bri Cancer 99: 2100, 2008.